GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Phoenix Biotech Acquisition Corp (NAS:PBAX) » Definitions » ROA %

Phoenix Biotech Acquisition (Phoenix Biotech Acquisition) ROA % : -11.83% (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Phoenix Biotech Acquisition ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Phoenix Biotech Acquisition's annualized Net Income for the quarter that ended in Sep. 2023 was $-1.34 Mil. Phoenix Biotech Acquisition's average Total Assets over the quarter that ended in Sep. 2023 was $11.29 Mil. Therefore, Phoenix Biotech Acquisition's annualized ROA % for the quarter that ended in Sep. 2023 was -11.83%.

The historical rank and industry rank for Phoenix Biotech Acquisition's ROA % or its related term are showing as below:

PBAX' s ROA % Range Over the Past 10 Years
Min: -4.84   Med: -0.6   Max: -0.6
Current: -4.84

During the past 2 years, Phoenix Biotech Acquisition's highest ROA % was -0.60%. The lowest was -4.84%. And the median was -0.60%.

PBAX's ROA % is not ranked
in the Diversified Financial Services industry.
Industry Median: -0.89 vs PBAX: -4.84

Phoenix Biotech Acquisition ROA % Historical Data

The historical data trend for Phoenix Biotech Acquisition's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phoenix Biotech Acquisition ROA % Chart

Phoenix Biotech Acquisition Annual Data
Trend Dec21 Dec22
ROA %
- -0.60

Phoenix Biotech Acquisition Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.19 -0.94 -6.79 -40.31 -11.83

Competitive Comparison of Phoenix Biotech Acquisition's ROA %

For the Shell Companies subindustry, Phoenix Biotech Acquisition's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Phoenix Biotech Acquisition's ROA % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Phoenix Biotech Acquisition's ROA % distribution charts can be found below:

* The bar in red indicates where Phoenix Biotech Acquisition's ROA % falls into.



Phoenix Biotech Acquisition ROA % Calculation

Phoenix Biotech Acquisition's annualized ROA % for the fiscal year that ended in Dec. 2022 is calculated as:

ROA %=Net Income (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=-0.668/( (180.078+42.367)/ 2 )
=-0.668/111.2225
=-0.60 %

Phoenix Biotech Acquisition's annualized ROA % for the quarter that ended in Sep. 2023 is calculated as:

ROA %=Net Income (Q: Sep. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Sep. 2023 ))/ count )
=-1.336/( (14.11+8.471)/ 2 )
=-1.336/11.2905
=-11.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2023) net income data. ROA % is displayed in the 30-year financial page.


Phoenix Biotech Acquisition  (NAS:PBAX) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Sep. 2023 )
=Net Income/Total Assets
=-1.336/11.2905
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-1.336 / 0)*(0 / 11.2905)
=Net Margin %*Asset Turnover
=N/A %*0
=-11.83 %

Note: The Net Income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Phoenix Biotech Acquisition ROA % Related Terms

Thank you for viewing the detailed overview of Phoenix Biotech Acquisition's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Phoenix Biotech Acquisition (Phoenix Biotech Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
2201 Broadway, Suite 705, Oakland, CA, USA, 94612
Website
Phoenix Biotech Acquisition Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company intends to pursue an acquisition opportunity in any business, industry, sector or geographical location, industries that complement management team's background, and to capitalize on the ability of management team to identify and acquire a business in the healthcare or healthcare related industries in the United States and Europe.
Executives
Caroline M Loewy director 300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Brian G Atwood director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kathleen Laporte director
Christopher B Ehrlich director, 10 percent owner, officer: CEO and and Secretary 499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158
Douglas Fisher officer: President 587 PATROL RD, WOODSIDE CA 94062
Daniel E. Geffken officer: Chief Financial Officer DAMONMILL SQUARE, SUITE 6A, CONCORD MA 01742
Barbara Kosacz director 3175 HANOVER STREET, PALO ALTO CA 94304
Phoenix Biotech Sponsor, Llc 10 percent owner 2001 MARKET STREET, SUITE 3400, PHILADELPHIA PA 19103